(Q28241360)

12 December 2020

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

1 reference

12 December 2020

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

1 reference

12 December 2020

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

1 reference

12 December 2020

New therapies for rheumatoid arthritis

1 reference

12 December 2020

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

12 December 2020

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

12 December 2020

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

12 December 2020

Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study

1 reference

12 December 2020

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Interleukin-6 in rheumatoid arthritis

1 reference

12 December 2020

British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).

1 reference

12 December 2020

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

12 December 2020

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

12 December 2020

1 reference

12 December 2020

Mortality in rheumatoid arthritis

1 reference

12 December 2020

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence

1 reference

12 December 2020

The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

1 reference

12 December 2020

New therapies for treatment of rheumatoid arthritis

1 reference

12 December 2020

Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.

1 reference

12 December 2020

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

1 reference

12 December 2020

Etanercept: a review of its use in the management of rheumatoid arthritis

1 reference

12 December 2020

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

1 reference

12 December 2020

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

12 December 2020

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

1 reference

12 December 2020

Use of biologics in rheumatoid arthritis: where are we going?

1 reference

12 December 2020

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

12 December 2020

Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again)

1 reference

12 December 2020

Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?

1 reference

12 December 2020

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

1 reference

12 December 2020

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

12 December 2020

Humanized antihuman IL-6 receptor antibody, tocilizumab

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

1 reference

12 December 2020

Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes

1 reference

12 December 2020

Interleukin-6: a new therapeutic target

1 reference

12 December 2020

Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis

1 reference

12 December 2020